-
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
(Hinzugefügt: 24.06.2022 um 07:29 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00307-3/fulltext
-
Study shows booster dose of Covaxin has neutralising effect on Omicron, Delta variants: Bharat Biotech Read more at: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-says-covaxin-booster-shot-neutralises-omi
(Hinzugefügt: 13.01.2022 um 11:12 Uhr)
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-says-covaxin-booster-shot-neutralises-omicron-variant/articleshow/88856831.cms?from=mdr
-
SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India
(Hinzugefügt: 11.01.2022 um 10:16 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787712
-
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study
(Hinzugefügt: 25.11.2021 um 18:35 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00674-5/fulltext
-
COVID-19: Totimpfstoff aus Indien in Phase-3-Studie wirksam
(Hinzugefügt: 19.11.2021 um 15:45 Uhr)
https://www.aerzteblatt.de/nachrichten/129075/COVID-19-Totimpfstoff-aus-Indien-in-Phase-3-Studie-wirksam
-
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
(Hinzugefügt: 15.11.2021 um 07:19 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02000-6/fulltext
-
Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19
(Hinzugefügt: 15.11.2021 um 07:18 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02014-6/fulltext
-
WHO lässt siebten Corona-Impfstoff zu
(Hinzugefügt: 04.11.2021 um 08:50 Uhr)
https://www.t-online.de/gesundheit/krankheiten-symptome/id_91080774/covaxin-who-laesst-siebten-corona-impfstoff-zu.html
-
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
(Hinzugefügt: 20.09.2021 um 09:33 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00462-X/fulltext
-
COVID-19 Vaccination: Delhi AIIMS likely to complete Covaxin trial on kids by next week
(Hinzugefügt: 19.07.2021 um 11:48 Uhr)
https://english.jagran.com/india/covid19-vaccination-delhi-aiims-likely-to-complete-covaxin-trial-on-kids-by-next-week-10029439
-
Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2
(Hinzugefügt: 17.07.2021 um 13:15 Uhr)
https://www.medrxiv.org/content/10.1101/2021.07.13.21260417v1
-
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial
(Hinzugefügt: 03.07.2021 um 17:49 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1
-
Covaxin Phase 3 Trial Analysis Conclude: Vaccine 77.8% Effective Against Covid, 65.2% Against Delta Variant
(Hinzugefügt: 03.07.2021 um 17:49 Uhr)
https://www.india.com/news/india/covaxin-phase-3-trials-conclude-vaccine-77-8-effective-against-covid-65-2-against-delta-variant-bharat-biotech-4785493/
-
Brazil suspends Covaxin contract after ‘serious accusations’ of irregularities
(Hinzugefügt: 01.07.2021 um 08:46 Uhr)
https://www.theguardian.com/world/2021/jun/29/brazil-cancels-covaxin-contract-after-serious-accusations-of-irregularities
-
Covaxin Phase 3 data in: Efficacy 77.8% against symptomatic Covid
(Hinzugefügt: 30.06.2021 um 15:31 Uhr)
https://indianexpress.com/article/india/covaxin-phase-3-data-in-efficacy-77-8-against-symptomatic-covid-7371293/
-
FDA rejects emergency use authorization for Bharat Biotech’s Covaxin jab
(Hinzugefügt: 11.06.2021 um 06:35 Uhr)
https://www.livemint.com/news/india/fda-rejects-eua-for-bharat-biotech-s-covaxin-jab-11623349228701.html
-
Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
(Hinzugefügt: 09.06.2021 um 19:31 Uhr)
https://www.biorxiv.org/content/10.1101/2021.06.05.447177v1
-
Covaxin effective against coronavirus strains found in India, UK
(Hinzugefügt: 17.05.2021 um 09:53 Uhr)
https://www.hindustantimes.com/india-news/covaxin-effective-against-coronavirus-strains-found-in-india-uk-101621154414188.html
-
COVAXIN® - India's First Indigenous COVID-19 Vaccine
(Hinzugefügt: 15.05.2021 um 09:51 Uhr)
https://www.bharatbiotech.com/covaxin.html
-
Covaxin found to neutralise 617 var .. Read more at: http://timesofindia.indiatimes.com/articleshow/82284139.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
(Hinzugefügt: 29.04.2021 um 07:21 Uhr)
https://timesofindia.indiatimes.com/india/covaxin-found-to-neutralise-617-variant-of-covid-19-dr-fauci/articleshow/82284139.cms
-
Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees
(Hinzugefügt: 25.04.2021 um 09:52 Uhr)
https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1
-
Covaxin neutralises double mutant strain: ICMR
(Hinzugefügt: 21.04.2021 um 14:07 Uhr)
https://www.cnbctv18.com/healthcare/covaxin-neutralises-double-mutant-strain-icmr-9008041.htm
-
Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease
(Hinzugefügt: 21.04.2021 um 14:06 Uhr)
https://www.bharatbiotech.com/images/press/covaxin-phase3-clinical-trials-interim-results.pdf
-
EXCLUSIVE-Ocugen plans to sell 100 mln Indian vaccine doses in U.S. in 2021
(Hinzugefügt: 26.03.2021 um 20:48 Uhr)
https://www.reuters.com/article/health-coronavirus-india-vaccine-idUSL4N2LD1FF
-
COVID-19 vaccine: Mexico experts recommend approving Bharat Biotech's Covaxin
(Hinzugefügt: 07.03.2021 um 08:17 Uhr)
https://www.newindianexpress.com/world/2021/mar/06/covid-19-vaccine-mexico-experts-recommend-approving-bharat-biotechs-covaxin-2273050.html
-
Covaxin vs Covishield: Your full guide
(Hinzugefügt: 07.03.2021 um 08:11 Uhr)
https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/covaxin-vs-covishield-your-full-guide-1774444-2021-03-01
-
Bharat Biotech’s Covaxin has around 81% efficacy: What does this mean for India?
(Hinzugefügt: 04.03.2021 um 15:23 Uhr)
https://indianexpress.com/article/explained/bharat-biotechs-covaxin-has-around-81-efficacy-what-does-this-mean-for-india-7212855/
-
Covaxin is effective against UK variant, shows study: what this means for India
(Hinzugefügt: 29.01.2021 um 20:40 Uhr)
https://indianexpress.com/article/explained/covaxin-is-effective-against-uk-variant-shows-study-what-this-means-for-india-7164596/
-
Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum
(Hinzugefügt: 27.01.2021 um 09:17 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.26.426986v1
-
India begins COVID-19 vaccination amid trial allegations
(Hinzugefügt: 22.01.2021 um 09:26 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00145-8/fulltext
-
Covaxin jabs possibly part of Bharat Biotech's Phase 3 trial
(Hinzugefügt: 17.01.2021 um 17:57 Uhr)
https://www.deccanchronicle.com/nation/current-affairs/160121/bharat-bios-phase-3-trial-with-consent-form.html
-
Vaccine makers in Asia rush to test jabs against fast-spreading COVID variant
(Hinzugefügt: 13.01.2021 um 08:29 Uhr)
https://www.nature.com/articles/d41586-021-00041-y
-
Covaxin: Concern over 'rushed' approval for India Covid jab
(Hinzugefügt: 05.01.2021 um 16:57 Uhr)
https://www.bbc.com/news/world-asia-india-55526123
-
Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine
(Hinzugefügt: 03.01.2021 um 19:59 Uhr)
https://pib.gov.in/PressReleseDetail.aspx?PRID=1685761
-
India's coronavirus vaccine approved by drugs experts
(Hinzugefügt: 03.01.2021 um 09:43 Uhr)
https://www.reuters.com/article/us-health-coronavirus-india-covaxin-time-idUSKBN2970KI